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Abstract
Summary This study estimated the incidence of osteonecrosis in a Swedish, nationwide cohort of older adults. Osteonecrosis was
approximately 10 times more common than in previous studies. The strongest risk factors were dialysis, hip fracture, osteomy-
elitis, and organ transplantation, but only hip fractures could have contributed substantially to the disease burden.
Introduction The aim of this study was to estimate the incidence of osteonecrosis in a Swedish, nationwide cohort of older adults
and in a large number of risk groups in that cohort.
Methods In this retrospective cohort study, we included everyone who was aged 50 years or older and who was living in Sweden on
31 December 2005. We used Swedish national databases to collect data about prescription medication use, diagnosed medical
conditions, and performed medical and surgical procedures. The study outcome was diagnosis of primary or secondary osteonecrosis
at any skeletal site. The strength of risk factors was assessed using age- and sex-standardized incidence ratios (SIRs).
Results The study cohort comprised 3,338,463 adults. The 10-year risk of osteonecrosis was 0.4% (n = 13,425), and the incidence rate
was 4.7 cases/10000 person-years (95% confidence interval [CI], 4.6 to 4.7 cases). The strongest risk factors for osteonecrosis were hip
fracture (SIR, 7.98; 95%CI, 7.69–8.27), solid organ transplantation (SIR, 7.14; 95%CI, 5.59–8.99), dialysis (SIR, 6.65; 95%CI, 5.62–
7.81), and osteomyelitis (SIR, 6.43; 95% CI, 5.70–7.23). A history of hip fracture was present in 21.7% of cases of osteonecrosis, but
osteomyelitis, dialysis, and solid organ transplantation were present in only 0.5 to 2% of cases.
Conclusions Osteonecrosis was approximately 10 times more common than a small number of previous population-based studies
have suggested. The strongest risk factors for osteonecrosis were dialysis, hip fracture, osteomyelitis, and solid organ transplan-
tation, but only hip fractures could have contributed substantially to the disease burden.
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Introduction
Osteonecrosis (or avascular necrosis) is a potentially painful
and disabling bone disease that involves the death of bone
tissue [1, 2]. Risk factors for osteonecrosis include fractures
[3–5], radiation [6, 7], corticosteroids [8, 9], excess alcohol
consumption [10], and a large number of medical conditions
[1, 2, 11–13]. The incidence of osteonecrosis in general pop-
ulations is uncertain because there have been few large,
population-based studies and because these few studies pri-
marily estimated the prevalence of osteonecrosis and the inci-
dence of particular types of osteonecrosis [14–19]. The inci-
dence has not been comprehensively assessed in risk groups,
as previous studies considered only one risk group or a limited
number of risk factors [5–7, 14, 15, 20–24].
A caveat when estimating the incidence of a disease in risk
groups is that any excess risk may be due to underlying char-
acteristics instead of the risk factor of interest. Indeed, the
causality of many of the medical conditions associated with
osteonecrosis is unclear, as is the true effect of risk factors that
are generally accepted as causal, such as corticosteroids [11,
12]. The aim of the present study was to determine how com-
mon osteonecrosis is in a general population and to identify
high-risk groups, irrespective of the underlying cause of the
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high risk. To do so, we estimated the incidence of
osteonecrosis in a Swedish, nationwide cohort of older adults
and in a large number of risk groups in that cohort.
Methods
Data collection and study cohort
This study, a retrospective cohort study, was based on data
collected from Swedish national databases, managed by
Statistics Sweden or the Swedish National Board of Health
andWelfare.We identified a study cohort using the Register of
the Total Population [25]. This cohort comprised everyone
aged 50 years or older who was living in Sweden on 31
December 2005.
Study outcome
The study outcome was diagnosis of primary (idiopathic) or
secondary osteonecrosis, made either during hospitalization or
at a visit to a specialist physician. This outcome included the
following International Classification of Diseases, 10th
Revision, (ICD-10) codes: M87 (osteonecrosis), M90.3
(osteonecrosis in Caisson disease), M90.4 (osteonecrosis due
to hemoglobinopathy), M90.5 (osteonecrosis in other diseases
classified elsewhere), M93.1 (Kienböck disease of adults),
and M93.2 (osteochondritis dissecans). Although
osteochondritis dissecans occurs mainly in children, we in-
cluded this diagnosis in this study of adults for completeness
[2]. Code K10.2 (osteonecrosis of the jaw) was not included
because it also covers conditions other than osteonecrosis.
We tracked the study outcome using the National Patient
Register, a database that records diagnoses made in any inpa-
tient care in Sweden since 1987 and any specialist outpatient
care since 2001 [26]. Diagnoses have been coded according to
the ICD-10 since 1997, and we did not have access to preva-
lence data about osteonecrosis prior to 1997.
Validation of study outcome
There are no published data about the validity of osteonecrosis
diagnoses in the National Patient Register. At present, the
most comprehensive validation study of this database is a
review which concluded that inpatient diagnoses are 85 to
95% correct, although this figure varied among conditions
and individual studies [26]. Outpatient diagnoses were not
assessed in that review.
Due to the lack of validation data for osteonecrosis diagno-
ses, one co-author (PN) obtained the identity of all patients
diagnosed with osteonecrosis (ICD-10 M87) at the University
Hospital of Umeå, Sweden. For a sample of 30 patients, med-
ical records were reviewed to validate the osteonecrosis
diagnosis and to identify possible causes. The 30 sampled
patients were aged 50 years or older, and they were the last
30 to be diagnosed with osteonecrosis at the hospital in 2016.
Risk factors
We collected data about diagnoses, medical procedures, sur-
gical procedures, and prescription medications that are poten-
tial risk factors for osteonecrosis according to highly cited
review articles [1, 2, 11–13]. We used the National Patient
Register to collect data about medical procedures, surgical
procedures, and diagnoses apart from cancer. Data about can-
cer were obtained from the Swedish Cancer Registry, which
records all cases of cancer diagnosed in Sweden since 1958
[27]. Data about prescription medications were obtained from
the Prescribed Drug Register, a database that records prescrip-
tion medications collected at pharmacies in Sweden since
July 2005 [28].
Supplemental Table 1 provides definitions of all included
risk factors, in terms of ICD codes, Anatomical Therapeutic
Chemical codes, and Klassifikation av kirurgiska åtgärder
1997 (Classification of Surgical Procedures 1997) codes.
Supplemental Table 1 also provides information about the
years for which the data were available.
Statistical analysis
Person-time at risk for osteonecrosis was the number of days
from baseline (31 December 2005) until osteonecrosis diag-
nosis, death, emigration from Sweden, or study endpoint (31
December 2015), whichever came first. Deaths were tracked
using the Cause of Death Register [29], and emigrations were
tracked using the Register of the Total Population [25].
Subjects who were diagnosed with osteonecrosis prior to
baseline did not contribute person-time.
Person-time at risk was grouped according to risk factors
for osteonecrosis. For medical conditions, medical proce-
dures, and surgical procedures, a subject contributed person-
time from the date of his or her first diagnosis or procedure (or
baseline if this came first). For hereditary, congenital, and
developmental conditions, a subject contributed person-time
from baseline irrespective of the date of diagnosis. For pre-
scription medications, a subject contributed person-time on
dates within 183 days (6 months) of a previously dispensed
medication. A subject could contribute person-time to more
than one risk factor.
We used standardized incidence ratios to compare the inci-
dence rate of osteonecrosis in risk groups to the incidence rate
in the general population. These ratios were indirectly stan-
dardized for sex and age (50–54, 55–59,…, ≥ 100 years), with
the risk groups serving as standards. We did not control for
confounders other than age and sex because we did not try to
estimate causal effects. One limitation of standardized
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incidence ratios is that they are not always comparable, as the
use of different standards can lead to residual confounding
[30]. Despite this limitation, we chose to use risk groups as
standards, instead of the general population, to reduce statis-
tical variability and to ensure that standardized incidence ra-
tios could be defined even in small risk groups in which not all
age groups were represented [30].
We also calculated age-specific incidence rates. These rates
were directly standardized for calendar year to control for
changes in incidence rates and diagnostic practices over time;
the overall population served as standard [30]. Confidence
intervals (CIs) for incidence rates and standardized incidence
ratios were estimated using Byar’s approximation [31].
Dates of events (diagnoses, medication dispensations,
births, deaths, and emigrations) were occasionally missing,
invalid, or incomplete (Supplemental Table 2). These events
were analyzed as occurring on the earliest possible dates.
Therefore, events for which the day was missing were as-
sumed to occur on the first of the month. Events for which
the month was missing were assumed to occur in January.
Events for which the year was missing were excluded to pre-
vent serious misclassification of person-time. All statistical
analyses were performed in R (Version 3.4.3) and RStudio
(Version 1.1.383).
Data linkage and ethics approval
Individual data were linked across databases using personal
identity numbers. A personal identity number is issued by the
Swedish Tax Agency to each resident of Sweden upon birth or
immigration. For privacy reasons, we obtained data files in
which personal identity numbers had been replaced by ran-
domly generated identifiers, created by Statistics Sweden.
This study was conducted according to the Declaration of
Helsinki, and it was approved by the Regional Ethical Review
Board in Umeå, Sweden (Dnr 2013-86-31M, 2013-304-32M,
and 2017-100-32M). Informed consent was not obtained be-
cause this requirement was waived by the Review Board.
Results
Study cohort and person-time at risk
Data were available for 3,347,958 residents of Sweden aged
50 years or older. We excluded the data of subjects who had a
suspected incorrect personal identity number (n = 199), had a
non-unique personal identity number because it was taken
from a deceased person (n = 3467), or had an out-of-range
date of birth (n = 1) or date of death (n = 52). With these ex-
clusions, the study cohort comprised 3,344,239 individuals.
Women constituted 53.0% (n = 1,771,035) of the cohort, and
the median age at baseline was 63.9 years (interquartile range,
57.2 to 74.5 years).
The baseline prevalence of osteonecrosis was 0.17% (n =
5776); it was 0.12% (n = 1864) among men and 0.22% (n =
3912) among women. These prevalent cases were excluded
from further analyses, and the remaining 3,338,463 subjects
contributed 28,862,867 person-years at risk. Of those who did
not develop osteonecrosis during the study, 73.6% (n =
2,448,858) were at risk for the full 10 years of follow-up,
25.4% (n = 845,094) died, and 0.9% (n = 31,086) emigrated
from Sweden.
Osteonecrosis in the general population
The 10-year risk of osteonecrosis was 0.40% (n = 13,425) in
the general population, 0.30% (n = 4713) in men, and 0.49%
(n = 8712) in women. The incidence rate of osteonecrosis was
4.7 cases/10000 person-years (95% CI, 4.6 to 4.7 cases).
Among men, the incidence rate was 3.5 cases/10000 person-
years (95% CI, 3.4 to 3.6 cases). Among women, it was 5.7
cases/10000 person-years (95% CI, 5.6 to 5.8 cases). The
incidence rate increased with age, although the 10-year risk
was approximately constant due to fewer person-years at risk
in older age groups (Table 1).
Osteonecrosis was diagnosed in outpatient care in 69.0%
(n = 9268) of cases. The most commonly affected skeletal
sites were the femur (46.2%), knee or lower leg (16.4%), foot
or ankle (7.4%), and shoulder (4.5%). The affected site was
unspecified in 23.4% of cases. Most cases were classified as
idiopathic (56.6%) or due to trauma (25.2%); the rest were
classified as due to cause unspecified (14.9%), medication
(1.9%), or disease (0.4%). Table 2 provides additional infor-
mation about these diagnoses.
Osteonecrosis in risk groups
The incidence of osteonecrosis was higher in almost all risk
groups than in the general population (Table 3). For some
small risk groups, such as for people with decompression
sickness, incidence rates and standardized incidence ratios
were not meaningful because confidence intervals were too
wide. Apart from decompression sickness, the standardized
incidence ratio was highest in people with a previous hip
fracture (7.98; 95% CI, 7.69–8.27), who constituted 21.7%
of cases of osteonecrosis. Standardized incidence ratios were
also high in people with osteomyelitis (6.43; 95% CI, 5.70–
7.23) and in people who had undergone dialysis (6.65; 95%
CI, 5.62–7.81) or solid organ transplantation (7.14; 95% CI,
5.59–8.99). Osteoarthritis was the most common comorbidity,
present in 47.6% of people diagnosed with osteonecrosis.
However, the standardized incidence ratio was not higher in
this group than in groups with other musculoskeletal or con-
nective tissue disorders (Table 3).
Osteoporos Int (2019) 30:965–973 967
The standardized incidence ratio was higher in people
who had undergone radiotherapy (3.03; 95% CI, 2.80–
3.27) than in people who had been diagnosed with can-
cer in general (1.40; 95% CI, 1.36–1.45). The standard-
ized incidence ratio was higher in people with systemic
corticosteroid use in the last 6 months (2.61; 95% CI,
2.50–2.73) than in people with non-systemic corticoste-
roid use in the last 6 months (1.15; 95% CI, 1.11–1.20).
Validation of osteonecrosis diagnoses
Radiographs, taken with plain radiography or computed tomog-
raphy, were available for all 30 reviewed osteonecrosis diagno-
ses. Twenty-seven (90%) of these diagnoses were judged correct,
2 (7%) were judged probably correct, and 1 (3%) was judged
incorrect. Of the correct diagnoses, 9 were related to musculo-
skeletal disease (6 osteoarthritis, 1 rheumatoid arthritis, 1 reactive
Table 1 Incidence rate and 10-
year risk of osteonecrosis accord-
ing to age
Age
50–59 60–69 70–79 80–89 ≥90
Incidence ratea, standardized 2.9 3.9 5.5 7.0 7.4
95% confidence interval 2.9–3.0 3.9–4.0 5.4–5.6 6.9–7.1 7.3–7.5
Casesb, n 1445 4490 3979 2878 633
Person-years, 10,000 569.5 1114.5 709.0 408.1 85.2
10-year risk, % 0.3 0.4 0.5 0.4 0.2
Cases†, n 3985 4228 3344 1691 177
Subjects at baseline, n 1,206,993 986,496 663,860 411,234 75,656
a Incidence rate/10,000 person-years, standardized for calendar year
b A different number of cases is tallied for the calculations of incidence rate and 10-year risk because subjects
could contribute person-time to more than one age group, but they remained in the same baseline age group
Table 2 Incidence rate of
osteonecrosis according to the
type of osteonecrosis diagnosis
Diagnosis Number of cases % of cases Rate/10,000 person-years (95% CI)
Total 13,425 100 4.7 (4.6–4.7)
Type
Osteonecrosis 12,351 92.0 4.3 (4.3–4.4)
Osteochondritis dissecans 903 6.7 0.3 (0.3–0.3)
Kienböck disease of adults 171 1.3 0.06 (0.05–0.07)
Site
Femur 6205 46.2 2.1 (2.1–2.2)
Unspecified 3137 23.4 1.1 (1.0–1.1)
Knee/lower leg 2204 16.4 0.8 (0.7–0.8)
Foot/ankle 989 7.4 0.3 (0.3–0.4)
Shoulder/upper arm 607 4.5 0.2 (0.2–0.2)
Hand/wrist 216 1.6 0.1 (0.1–0.1)
Multiple sites 34 0.3 0.01 (0.008–0.02)
Elbow/forearm 33 0.2 0.01 (0.008–0.02)
Cause
Idiopathic 7596 56.6 2.6 (2.6–2.7)
Trauma 3521 26.2 1.2 (1.2–1.3)
Unspecified 2004 14.9 0.7 (0.7–0.7)
Medication 250 1.9 0.1 (0.1–0.1)
Other disease 47 0.4 0.02 (0.01–0.02)
Hemoglobinopathy 5 0.0 0.002 (0.0006–0.004)
Decompression 2 0.0 0.0007 (0.00008–0.003)
Diagnoses were classified according to the International Classification of Diseases, 10th Revision, Swedish
Version
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Table 3 Incidence rate of osteonecrosis according to risk factor
Risk factor No. of cases % of cases Rate/10000 person-years (95% CI) Standardized incidence ratio (95% CI)
Population 13,425 100 4.7 (4.6–4.7) 1
Chronic kidney disease 281 2.1 15.4 (13.7–17.3) 3.15 (2.79–3.54)
Cancer 3636 27.1 7.4 (7.2–7.6) 1.40 (1.36–1.45)
External exposures
Decompression sickness 1 0.0 37.5 (0.5–208.5) 13.10 (0.17–72.90)
Solid organ transplantation 72 0.5 26.8 (20.9–33.7) 7.14 (5.59–8.99)
Dialysis 147 1.1 29.0 (24.5–34.0) 6.65 (5.62–7.81)
Radiotherapy 664 4.9 14.8 (13.7–16.0) 3.03 (2.80–3.27)
Corticosteroidsa, systemic 2056 15.3 13.7 (13.1–14.3) 2.61 (2.50–2.73)
Mental/behavioral disorder due to alcohol use 582 4.3 10.0 (9.2–10.8) 2.61 (2.40–2.83)
Corticosteroidsa, nonsystemic 2618 19.5 5.7 (5.5–5.9) 1.15 (1.11–1.20)
Infectious diseases
HIV/AIDS 15 0.1 14.7 (8.2–24.3) 4.28 (2.39–7.06)
Meningococcal infection 5 0.0 16.9 (5.4–39.4) 3.37 (1.09–7.86)
Blood disorders
Sickle-cell disorders 7 0.1 23.0 (9.2–47.4) 4.72 (1.89–9.73)
Disseminated intravascular coagulation 4 0.0 13.7 (3.7–35.0) 2.76 (0.74–7.06)
Polycythemia, secondary 18 0.1 5.7 (3.4–9.1) 1.29 (0.76–2.04)
Thalassemia 3 0.0 4.6 (0.9–13.4) 1.05 (0.21–3.08)
Hemophilia 2 0.0 4.0 (0.5–14.6) 0.91 (0.10–3.28)
Endocrine/metabolic disorders
Cushing syndrome 10 0.1 14.0 (6.7–25.7) 2.92 (1.40–5.38)
Hyperparathyroidism 141 1.1 9.7 (8.1–11.4) 1.63 (1.37–1.92)
Diabetes mellitus 1653 12.3 7.2 (6.9–7.6) 1.44 (1.37–1.51)
Hypercholesterolemia/hyperlipidemia 1257 9.4 6.4 (6.1–6.8) 1.33 (1.25–1.40)
Gaucher disease 0 0
Fabry-Anderson disease 0 0
Vascular diseases
Arteriosclerosis 605 4.5 13.7 (12.6–14.8) 2.47 (2.28–2.68)
Raynaud syndrome 24 0.2 9.6 (6.1–14.2) 2.02 (1.29–3.00)
Phlebitis/thrombophlebitis 654 4.9 9.1 (8.4–9.8) 1.73 (1.60–1.86)
Gastrointestinal diseases
Inflammatory bowel disease 551 4.1 8.3 (7.6–9.0) 1.67 (1.53–1.81)
Pancreatitis 206 1.5 6.7 (5.8–7.6) 1.36 (1.18–1.55)
Musculoskeletal/connective tissue disorders
Osteomyelitis 279 2.1 31.2 (27.6–35.1) 6.43 (5.70–7.23)
Osteomalacia 7 0.1 19.0 (7.6–39.1) 3.75 (1.50–7.73)
Polymyositis 15 0.1 17.3 (9.7–28.5) 3.46 (1.93–5.71)
Systemic lupus erythematosus 53 0.4 16.9 (12.7–22.1) 3.25 (2.44–4.26)
Osteoarthritis 6396 47.6 16.3 (15.9–16.7) 3.06 (2.98–3.13)
Osteoporosis 1233 9.2 19.9 (18.8–21.0) 2.94 (2.78–3.11)
Polymyalgia rheumatica 445 3.3 17.1 (15.5–18.8) 2.67 (2.42–2.93)
Rheumatoid arthritis 645 4.8 13.2 (12.2–14.3) 2.45 (2.27–2.65)
Gout 307 2.3 12.1 (10.8–13.6) 2.45 (2.18–2.74)
Giant cell arteritis 162 1.2 14.5 (12.3–16.9) 2.30 (1.96–2.68)
Sjögren/sicca syndrome 123 0.9 11.6 (9.6–13.8) 2.04 (1.69–2.43)
Ankylosing spondylitis 52 0.4 6.9 (5.2–9.1) 1.74 (1.30–2.28)
Congenital/developmental disorders
Slipped upper femoral epiphysis, nontraumatic 1 0.0 20.8 (0.3–115.6) 4.34 (0.06–24.14)
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arthropathy, and 1 polymyalgia rheumatica), 8 to cancer or can-
cer therapy (e.g., radiotherapy, chemotherapy, or corticosteroids),
7 to fracture (including 1 idiopathic fracture of the acetabulum), 2
to osteoporosis medication (zoledronic acid), and 1 to surgery for
hallux valgus. Of the probably correct diagnoses, 1 was related to
hip fracture and 1 to proximal tibia fracture and knee osteoarthri-
tis. The 1 incorrect diagnosis was a case of critical ischemia in a
toe, related to severe atherosclerosis, but radiographs showed no
sign of osteonecrosis.
Discussion
Among older adults in Sweden, the incidence of osteonecrosis
was 4.7 cases/10000 person-years. The strongest risk factors for
osteonecrosis were dialysis, osteomyelitis, hip fracture, and solid
organ transplantation. Few previous studies have estimated the
incidence of osteonecrosis in a general population, but two stud-
ies that did, one in Denmark and one in the UK, showed yearly
rates of 1/10th or less than our study did [14, 15]. Our cohort was
older, but this difference cannot explain the entire difference
because the UK study showed a considerably lower incidence
in older adults as well [15]. Possible explanations for the differ-
ence in incidence include geographic variation, a greater
propensity of Swedish physicians to diagnose osteonecrosis,
and a more complete coverage of specialist health care in the
database we used to identify osteonecrosis, although the Danish
study used a similar national database [14].
The current study showed a history of hip fracture in 22%
of older adults diagnosed with osteonecrosis at any skeletal
site. Previous large, population-based studies of osteonecrosis
did not report the prevalence of hip fracture [14, 15], and a
single-center study of osteonecrosis of the femoral head attrib-
uted only 13% of cases to hip fractures [22]. Hip fracture is a
well-known risk factor for osteonecrosis of the femoral head,
and the risk varies depending on the type of hip fracture and
surgical procedure [32, 33]. Unfortunately, our study could
not adequately distinguish between osteonecrosis of the fem-
oral head and other types of osteonecrosis, as the skeletal site
was often unspecified. Nevertheless, it is clear that a large
percentage of people diagnosed with osteonecrosis at some
skeletal site had a history of hip fracture.
Dialysis, osteomyelitis, and solid organ transplantation were
also associated with a high incidence of osteonecrosis, but these
risk factors were only present in 0.5 to 2% of cases of
osteonecrosis. A previous population-based study showed a sim-
ilar result for solid organ transplantation [15], but this study did
not examine osteomyelitis and it examined dialysis only in
Table 3 (continued)
Risk factor No. of cases % of cases Rate/10000 person-years (95% CI) Standardized incidence ratio (95% CI)
Legg-Calvé-Perthes disease 5 0.0 16.0 (5.2–37.4) 4.13 (1.33–9.65)
Juvenile rheumatoid arthritis 10 0.1 11.1 (5.3–20.4) 2.19 (1.05–4.02)
Hip deformity 8 0.1 10.3 (4.4–20.3) 1.92 (0.83–3.78)
Ehlers-Danlos syndrome 3 0.0 6.0 (1.2–17.6) 1.47 (0.30–4.29)
Trauma
Fracture
Hip 2915 21.7 54.3 (52.3–56.3) 7.98 (7.69–8.27)
Upper arm 956 7.1 18.3 (17.1–19.5) 2.93 (2.75–3.12)
Knee 404 3.0 11.6 (10.5–12.8) 2.08 (1.88–2.30)
Foot 312 2.3 9.8 (8.7–11.0) 2.07 (1.84–2.31)
Hand 456 3.4 8.9 (8.1–9.7) 1.88 (1.71–2.06)
Dislocation
Hip 41 0.3 17.4 (12.5–23.5) 2.89 (2.07–3.92)
Shoulder 183 1.4 11.2 (9.6–13.0) 2.19 (1.88–2.53)
Knee 15 0.1 10.0 (5.6–16.5) 2.20 (1.23–3.64)
Injury of blood vessel
Hip 5 0.0 19.1 (6.2–44.6) 3.84 (1.24–8.97)
Shoulder 2 0.0 8.6 (1.0–31.0) 1.93 (0.22–6.98)
Lower leg 1 0.0 4.4 (0.1–24.4) 0.92 (0.01–5.09)
Burns/corrosions 71 0.5 6.6 (5.1–8.3) 1.64 (1.28–2.07)
Fat embolism 0 0
CI, confidence interval
a Corticosteroid use defined as having collected a prescription in the last 6 months
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combination with renal failure. Osteonecrosis is part of the pa-
thology of osteomyelitis [34], but it is less clear why dialysis and
solid organ transplantation are associated with a high risk. One
explanation is the use of high-dose corticosteroids in patients
undergoing solid organ transplantation [12]. Another explana-
tion, which has been suggested for both dialysis and solid organ
transplantation, is increased secretion of parathyroid hormone
[12]. Our study indicates that dialysis, osteomyelitis, and solid
organ transplantation do not contribute substantially to the bur-
den of osteonecrosis in the general population. However, our
results also indicate that osteonecrosis is a real concern in these
risk groups.
As with solid organ transplantation, many medical condi-
tions may be associated with osteonecrosis due to the use of
systemic corticosteroids [12]. The present study showed that
systemic corticosteroid use in the last 6 months was a strong,
but not one of the strongest, risk factors for osteonecrosis. It
was present in 15% of cases, which is similar to the results of
some previous studies [15, 19]. However, studies of non-
traumatic osteonecrosis of the femoral head have attributed
50% or more of cases to corticosteroids [16–18]. Our results
may not be generalizable to ever or high-dose corticosteroid
users or to patients with non-traumatic osteonecrosis, but our
results suggest that recent corticosteroid use can explain at
most a minority of cases of osteonecrosis.
Previous studies have shown a high risk of osteonecrosis in
people with systemic lupus erythematosus [35, 36]. In our
study, this disease was not a stronger risk factor for
osteonecrosis than were several other musculoskeletal and
connective tissue diseases. Data are lacking from other
population-based studies to verify this result. It may apply
only to older adults, as systemic lupus erythematosus tends
to develop in younger adults [36].
Our study showed that almost 50% of people diagnosed with
osteonecrosis also had osteoarthritis. A large part of this high
prevalence appeared to be due to a high prevalence of osteoar-
thritis in the general population, as osteoarthritis was not a stron-
ger risk factor for osteonecrosis than were other musculoskeletal
diseases. The analysis was only controlled for age and sex, as we
did not try to determine causality, but a previous retrospective
cohort study showed that osteoarthritis was one of the strongest
risk factors for osteonecrosis after adjustment for multiple con-
founders [15]. Osteoarthritis has long been discussed as a possi-
ble cause of osteonecrosis [37, 38]. However, it is rarely listed as
a risk factor in review articles [1, 2, 11–13], so this type of
osteonecrosis could be underdiagnosed. On the other hand,
osteonecrosis could be overdiagnosed in our and in previous
retrospective cohort studies since the two conditions have similar
symptoms [2]. To complicate matters further, osteonecrosis itself
is a risk factor for osteoarthritis, as late-stage osteonecrosis is
characterized by joint destruction [23]. More research is needed
to determine whether osteoarthritis increases the risk of
osteonecrosis. To minimize confounding and misclassification
bias, this research should preferably be based on patient data that
are more detailed than the data available in most retrospective
cohort studies.
Five limitations of this study should be noted. First, we vali-
dated only a convenience sample of 30 osteonecrosis diagnoses
made at one university hospital. Second, we did not study
osteonecrosis of the jaw, which has been related to osteoporosis
treatment [39], because osteonecrosis of the jaw does not have a
specific ICD-10 code. Third, the prevalence of osteonecrosis was
probably underestimated, as data about osteonecrosis were avail-
able only from 1997. Fourth, the prevalence of some risk factors
was probably also underestimated because the National Patient
Register has a low sensitivity for many conditions, especially
those managed in primary care [26]. Since mild conditions are
more likely to bemanaged in primary care than severe conditions
are, our resultsmay not be generalizable tomild conditions. Fifth,
we could not completely determine the role of alcohol consump-
tion in osteonecrosis because we only had data about a surrogate
of high alcohol consumption.
In sum, this nationwide study of older adults in Sweden
showed that osteonecrosis was approximately 10 times more
common than a small number of previous population-based stud-
ies have suggested. The strongest risk factors for osteonecrosis
were dialysis, osteomyelitis, hip fracture, and solid organ trans-
plantation. Although this study did not attempt to estimate causal
effects, only hip fractures could have contributed substantially to
the disease burden, as hip fractures were present in one fifth of
older adults diagnosed with osteonecrosis at various skeletal
sites. Dialysis, osteomyelitis, and solid organ transplantation
were rare among older adults diagnosed with osteonecrosis, but
the high incidence in these groups is concerning.
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